crwefinancelogo2
signup3m
PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's successful international approach to commercializing its proprietary and patent pending stem cell technologies.
Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted:
1. In the past few months the Company has undertaken an intensive international effort to establish strategic joint ventures in several European and Mid-Eastern nations for our Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI). We may be able to finalize the terms and conditions on at least one agreement arising from this initiative in the short term.
As a reminder, PRTMI's mission is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. We have had discussions regarding the creation of clinics in more one than one country and we believe that we may be able to eventually open such regenerative medicine clinics in Europe and/or the Middle East in the coming year.
2. Of course, we intend that such clinics will operate under the strictest cGMP guidelines allowing us to use the clinical information generated for our future discussions with the FDA, which would be helpful in pursuing the more arduous process for eventually establishing regenerative medicine clinics in the United States.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.
Cell Therapeutics, Inc. (Nasdaq:CTIC) recently reported it has filed for a Special Protocol Assessment with the U.S. Food and Drug Administration for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma. In the filing, CTI proposed to the FDA that the randomized study will compare pixantrone plus rituximab against the current standard regimens used to treat this patient group. This trial is planned to enroll relapsed or refractory aggressive B-Cell NHL patients who failed first-line to third-line treatment with standard chemotherapy and are not transplant eligible.
CTIC a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkin?s lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma.
St. Jude Medical, Inc. (NYSE:STJ) a global medical device company, recently reported that it has filed a lawsuit against Volcano Corporation for patent infringement, which involves five St. Jude Medical patents and seeks injunctive relief and monetary damages, and was filed in the United States District Court for the District of Delaware. The lawsuit alleges that several products distributed by Volcano, including its PrimeWire pressure guide wire products, infringe on key patents used for the St. Jude Medical PressureWire technology platform.
STJ develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
signup3m
PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, is pleased to provide an update on the Company's successful international approach to commercializing its proprietary and patent pending stem cell technologies.
Mr. Michael Cohen, Chairman and CEO of Proteonomix, noted:
1. In the past few months the Company has undertaken an intensive international effort to establish strategic joint ventures in several European and Mid-Eastern nations for our Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI). We may be able to finalize the terms and conditions on at least one agreement arising from this initiative in the short term.
As a reminder, PRTMI's mission is to translate the most promising internal and external stem cell biology and cellular therapy to clinical applications of regenerative medicine. We have had discussions regarding the creation of clinics in more one than one country and we believe that we may be able to eventually open such regenerative medicine clinics in Europe and/or the Middle East in the coming year.
2. Of course, we intend that such clinics will operate under the strictest cGMP guidelines allowing us to use the clinical information generated for our future discussions with the FDA, which would be helpful in pursuing the more arduous process for eventually establishing regenerative medicine clinics in the United States.
PROT is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products.
Cell Therapeutics, Inc. (Nasdaq:CTIC) recently reported it has filed for a Special Protocol Assessment with the U.S. Food and Drug Administration for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma. In the filing, CTI proposed to the FDA that the randomized study will compare pixantrone plus rituximab against the current standard regimens used to treat this patient group. This trial is planned to enroll relapsed or refractory aggressive B-Cell NHL patients who failed first-line to third-line treatment with standard chemotherapy and are not transplant eligible.
CTIC a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkin?s lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma.
St. Jude Medical, Inc. (NYSE:STJ) a global medical device company, recently reported that it has filed a lawsuit against Volcano Corporation for patent infringement, which involves five St. Jude Medical patents and seeks injunctive relief and monetary damages, and was filed in the United States District Court for the District of Delaware. The lawsuit alleges that several products distributed by Volcano, including its PrimeWire pressure guide wire products, infringe on key patents used for the St. Jude Medical PressureWire technology platform.
STJ develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)
Source...